An interventional study of Test Dentifrice and Colgate Sensitive ProRelief in Dentin Sensitivity, sponsored by HALEON. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by HALEON · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 4 under way, none of them phase 3. Dentin Sensitivity · HALEON.
Among the 21 studies in Dentin Sensitivity by HALEON, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2013, is one of 18 with no phase, and was the 16th registered.
290 studies on the registry are indexed under Dentin Sensitivity; 47 are open to participants now.
Browse Dentin Sensitivity studies →3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:
HALEON · Sites in Canada
Ages 18+ · Healthy volunteers
HALEON · Sites in United States
Ages 18+ · Healthy volunteers
HALEON · Sites in United Kingdom
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 18 Dentin Sensitivity studies recruiting now, 6 (33%) set no upper age limit and 11 (61%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2013.
This study's enrollment of 120 is above the median of 60 across 280 interventional studies indexed under Dentin Sensitivity.
Median enrollment 185 across the 20 interventional studies, 375 across the 1 observational. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
4 of the studies in Dentin Sensitivity by HALEON that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07300540HALEONReal-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief | 2026-11 |
| NCT07894796HALEONA Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-01 |
| NCT07337109HALEONA Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers | 2027-02 |
| NCT07802886HALEONA Clinical Study to Assess the Efficacy of a Calcium Sodium Phosphosilicate Toothpaste for the Relief of Dentine Hypersensitivity | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Dentin Sensitivity by HALEON, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the clinical efficacy of test fluoride dentifrice in reducing Dentin Hypersensitivity (DH) with that of a standard fluoride dentifrice, as measured by evaporative air sensitivity after 12 weeks twice daily brushing.
A randomized, examiner blind, three treatment arm, parallel group design with a treatment period of 12 weeks. Approximately 275 participants will be screened to ensure that approximately 120 participants to be randomized (approximately 40 to each treatment group) and at least 114 participants to complete the study (approximately 38 per treatment group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant with good general and mental health, in the opinion of the investigator or medically qualified designee:
Exclusion Criteria:
Participant with Specific Dentition Exclusions for Test teeth.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be instructed to apply a full ribbon of test dentifrice to cover the head of the assigned toothbrush and brush twice daily for 1 timed minute throughout the 12-week treatment period.
Drug: Test Dentifrice
Participants will be instructed to apply a full ribbon of the comparator dentifrice to cover the head of the assigned toothbrush and brush twice daily for 1 timed minute throughout the 12-week treatment period.
Drug: Colgate Sensitive ProRelief
Participants will be instructed to apply a full ribbon of the negative control dentifrice to cover the head of the assigned toothbrush and brush twice daily for 1 timed minute throughout the 12-week treatment period.
Drug: Colgate Triple Protection
Dentifrice containing 1450 parts per million (ppm) fluoride as sodium monofluorophosphate.
A marketed dentifrice.
A marketed dentifrice.
Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Week 12 (Test Dentifrice Versus [vs] Negative Control Dentifrice)
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0 equal to (=) no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoint.
Time frame: Baseline and Week 12
Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Weeks 2, 4 and 8 (Test Dentifrice vs Negative Control Dentifrice)
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, and 8
Adjusted Mean Change From Baseline in Visual Analogue Scale (VAS) at Weeks 2, 4, 8 and 12 (Test Dentifrice vs Negative Control Dentifrice)
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 millimeter (mm) VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in Tactile Threshold at Weeks 2, 4, 8 and 12 (Test Dentifrice vs Negative Control Dentifrice)
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (grams \[g\]). Higher tactile threshold indicated a better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Weeks 2, 4, 8 and 12 (Comparator Dentifrice vs Negative Control Dentifrice)
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in VAS at Weeks 2, 4, 8 and 12 (Comparator Dentifrice vs Negative Control Dentifrice)
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 mm VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in Tactile Threshold at Weeks 2, 4, 8 and 12 (Comparator Dentifrice vs Negative Control Dentifrice)
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (g). Higher tactile threshold indicated better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Weeks 2, 4, 8 and 12 (Test Dentifrice vs Comparator Dentifrice)
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in VAS at Weeks 2, 4, 8 and 12 (Test Dentifrice vs Comparator Dentifrice)
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 mm VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
Adjusted Mean Change From Baseline in Tactile Threshold at Weeks 2, 4, 8 and 12 (Test Dentifrice vs Comparator Dentifrice)
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (g). Higher tactile threshold indicated better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
Time frame: Baseline, Weeks 2, 4, 8 and 12
This study was conducted at a single center in China.
| Milestone | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice |
|---|---|---|---|
| Started | 42 | 40 | 38 |
| Completed | 42 | 40 | 38 |
| Not completed | 0 | 0 | 0 |
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0 equal to (=) no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoint.
| score on a scale | Test Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Week 12 (Test Dentifrice Versus [vs] Negative Control Dentifrice) | -1.19 ± 0.108 | -0.44 ± 0.084 |
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
| score on a scale | Test Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | -0.44 ± 0.066 | -0.06 ± 0.057 |
| Week 4 | -0.67 ± 0.081 | -0.20 ± 0.061 |
| Week 8 | -0.92 ± 0.096 | -0.47 ± 0.072 |
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 millimeter (mm) VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| score on a scale | Test Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | -7.69 ± 2.149 | -6.74 ± 2.833 |
| Week 4 | -12.99 ± 3.084 | -12.59 ± 2.748 |
| Week 8 | -21.80 ± 3.236 | -16.81 ± 3.374 |
| Week 12 | -29.21 ± 4.028 | -19.47 ± 3.917 |
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (grams \[g\]). Higher tactile threshold indicated a better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| g | Test Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | 8.69 ± 1.815 | 3.48 ± 1.065 |
| Week 4 | 13.92 ± 2.894 | 5.02 ± 1.843 |
| Week 8 | 19.67 ± 2.744 | 5.46 ± 1.709 |
| Week 12 | 31.64 ± 3.870 | 7.76 ± 1.948 |
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
| score on a scale | Comparator Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | -0.69 ± 0.079 | -0.06 ± 0.057 |
| Week 4 | -0.80 ± 0.084 | -0.20 ± 0.061 |
| Week 8 | -1.10 ± 0.097 | -0.47 ± 0.072 |
| Week 12 | -1.44 ± 0.093 | -0.44 ± 0.084 |
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 mm VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| score on a scale | Comparator Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | -9.28 ± 3.053 | -6.74 ± 2.833 |
| Week 4 | -14.40 ± 2.844 | -12.59 ± 2.748 |
| Week 8 | -20.94 ± 3.687 | -16.81 ± 3.374 |
| Week 12 | -28.79 ± 3.617 | -19.47 ± 3.917 |
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (g). Higher tactile threshold indicated better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| g | Comparator Dentifrice | Negative Control Dentifrice |
|---|---|---|
| Week 2 | 9.54 ± 1.725 | 3.48 ± 1.065 |
| Week 4 | 14.37 ± 2.226 | 5.02 ± 1.843 |
| Week 8 | 17.05 ± 2.505 | 5.46 ± 1.709 |
| Week 12 | 28.54 ± 3.573 | 7.76 ± 1.948 |
Evaporative (air) sensitivity was evaluated using the Schiff Sensitivity Score on test teeth for each participant. After the examiner applied a standardized air stimulus, the participant's response was rated on a 0 to 3 scale, where 0= no response to the stimulus, 1= response to air stimulus without request for discontinuation of the stimulus, 2= response to air stimulus with request for discontinuation of the stimulus, and 3= a painful response with a request for discontinuation of the stimulus. Lower score indicated improvement. Change from Baseline was calculated by subtracting the Baseline score from the score at indicated timepoints.
| score on a scale | Test Dentifrice | Comparator Dentifrice |
|---|---|---|
| Week 2 | -0.44 ± 0.066 | -0.69 ± 0.079 |
| Week 4 | -0.67 ± 0.081 | -0.80 ± 0.084 |
| Week 8 | -0.92 ± 0.096 | -1.10 ± 0.097 |
| Week 12 | -1.19 ± 0.108 | -1.44 ± 0.093 |
Evaporative (air) sensitivity was assessed on the test teeth by applying a 1-second air stimulus from a standard dental syringe. Participants rated the intensity of their response to the evaporative (air) stimulus using a 100 mm VAS with scores ranging from 0 mm (No discomfort) to 100 mm (Extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| score on a scale | Test Dentifrice | Comparator Dentifrice |
|---|---|---|
| Week 2 | -7.69 ± 2.149 | -9.28 ± 3.053 |
| Week 4 | -12.99 ± 3.084 | -14.40 ± 2.844 |
| Week 8 | -21.80 ± 3.236 | -20.94 ± 3.687 |
| Week 12 | -29.21 ± 4.028 | -28.79 ± 3.617 |
Tactile sensitivity was assessed for eligible teeth using a constant pressure probe (Yeaple probe). After each application of the stimulus, participants were asked to indicate whether they experienced any pain or discomfort (yes/no response). The pressure setting with two consecutive 'yes' responses was recorded as the tactile threshold (g). Higher tactile threshold indicated better outcome (less sensitivity). Change from Baseline was calculated by subtracting Baseline value from the value at indicated timepoints.
| g | Test Dentifrice | Comparator Dentifrice |
|---|---|---|
| Week 2 | 8.69 ± 1.815 | 9.54 ± 1.725 |
| Week 4 | 13.92 ± 2.894 | 14.37 ± 2.226 |
| Week 8 | 19.67 ± 2.744 | 17.05 ± 2.505 |
| Week 12 | 31.64 ± 3.870 | 28.54 ± 3.573 |
Collected over Immediately from the start of the investigational product (or washout product), and until 5 days following last administration of the investigational product (Approximately up to 117 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Dentifrice | 0/42 (0%) | 0/42 (0%) | 2/42 (4.8%) |
| Comparator Dentifrice | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Negative Control Dentifrice | 0/38 (0%) | 0/38 (0%) | 0/38 (0%) |
| Event | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice |
|---|---|---|---|
| HypertensionVascular disorders | 0/42 | 1/40 | 0/38 |
| NasopharyngitisInfections and infestations | 0/42 | 1/40 | 0/38 |
| Mouth UlcerationGastrointestinal disorders | 1/42 | 0/40 | 0/38 |
| PharyngitisInfections and infestations | 1/42 | 0/40 | 0/38 |
Safety Population was defined as all participants who were randomised and administered at least one study treatment during the study.
| Age, Continuous(years) | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice | Total |
|---|---|---|---|---|
| Mean | 40.4 ± 9.06 | 40.8 ± 6.49 | 39.1 ± 6.95 | 40.1 ± 7.59 |
| Sex: Female, Male(Participants) | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice | Total |
|---|---|---|---|---|
| Female | 37 | 36 | 31 | 104 |
| Male | 5 | 4 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 42 | 40 | 38 | 120 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Test Dentifrice | Comparator Dentifrice | Negative Control Dentifrice | Total |
|---|---|---|---|---|
| Asian | 42 | 40 | 38 | 120 |
Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
No publications or documents are linked to this record.
Ran from Jan 2013 to primary completion in Jun 2013, 4 months.
Results were first posted in May 2026, 12 years 11 months after primary completion.
Of 33 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 4 months is above that.
Counting every sponsor, half of 144 studies reached it within 6 months; a quarter within 3 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.